GlaxoSmithKline named former Novartis executive Brian McNamara as the new CEO of the GSK Consumer Healthcare entity, following Emma Walmsley's promotion to GSK global CEO. He previously headed the OTC

GlaxoSmithKline named Emma Walmsley as its next CEO. She will succeed Sir Andrew Witty in March 2017, becoming arguably the most powerful woman in the UK corporate sector. Although five other FTSE 100

GlaxoSmithKline is joining forces with tech developer Verily - a unit of Google parent Alphabet Inc - to develop "bioelectronic" medicines to combat diseases such as arthritis, diabetes and asthma. This

GlaxoSmithKline concluded a review of marketing for its consumer healthcare division, consolidating duties with nine of its main current partners and eliminating other agencies from the roster. Grey and

GlaxoSmithKline CEO Andrew Witty confirmed plans to step down in a year's time. Though insiders such as CFO Simon Dingemans will be considered for the job, an outsider candidate is more likely. "I believe

The split was prompted in part by GlaxoSmithKline's recent acquisition of the vaccines previously controlled by Novartis, which has allowed it to leapfrog both its rivals and become the new global #1.

a unit of GlaxoSmithKline. It will continue to market its current portfolio of approved HIV drugs including Sustiva, Reyataz and Atripla. The price of the deal could be up to $2.9bn depending on the future

GlaxoSmithKline was the latest global marketing giant to join the so-called "mediapalooza", an unprecedented wave of global media reviews, in which more than 20 global groups have called pitches. GSK'